RBM5 and acute myeloid leukemia: A competitive proliferation assay (CPA) was conducted to exhibit that disruption of RBM5 impaired the cell growth of three AML lines (MOLM13, THP1, OCIAML2) but had a mild effect on the three other cell lines (U937, HEL, TF1) (Fig. 2a).